Article

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2

2023-07-25

Abstract excerpt

<h4>Background</h4> Immune checkpoint inhibitors (ICIs) and their combination with other therapies such as chemotherapy, fail in most cancer patients. We previously identified the PDZ-LIM domain-containing protein 2 (PDLIM2) as a bona fide tumor suppressor that is repressed in lung cancer to drive cancer and its chemo and immunotherapy resistance, suggesting a new target for lung cancer therapy improvement. <h4...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ec145c5d-b54b-56d6-aa2b-9c0ea29f9bfd
DOI: 10.1101/2023.07.23.550248

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2DOI 10.1101/2023.07.23.550248Read

Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistanceSemantic proximity Read

PDLIM2 in Lung Adenocarcinoma MetastasisSemantic proximity Read

Modern therapies of nonsmall cell lung cancerSemantic proximity Read

FOXM1 targeting alters AURKB activity and reshapes antitumor immunity to curb the progression of small cell lung cancerSemantic proximity Read

Nanomedicine Strategies for Management of Drug Resistance in Lung CancerSemantic proximity Read

The SARS-CoV-2 host cell membrane fusion protein TMPRSS2 is a tumor suppressor and its downregulation correlates with increased antitumor immunity and immunotherapy response in lung adenocarcinomaSemantic proximity Read

LIMD1 Loss as an Early Driver of PD-L1 Upregulation and Immune Evasion in Lung CancerSemantic proximity Read

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized MedicineSemantic proximity Read

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse modelSemantic proximity Read

Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective studySemantic proximity Read

siRNA-based Therapeutic Candidate Targeting PRDM2 for Inhibition of Lung Cancer ProgressionSemantic proximity Read

Multi-compartment immune and tumor cell reprogramming by IFNα2 overcomes colon cancer immunotherapy resistanceSemantic proximity Read